| The Protection Conferred by HSD17B13 rs72613567 on Hepatic Fibrosis Is Likely Mediated by Lowering Ballooning and Portal Inflammation. | The Protection Conferred by HSD17B13 rs72613567 on Hepatic Fibrosis Is Likely Mediated by Lowering Ballooning and Portal Inflammation.
Vilar-Gomez E, Liang T, Yates K, Wilson L, Loomba R, Chalasani N., | 09/26/2023 |
| Association of HSD17B13 and PNPLA3 With Liver Enzymes and Fibrosis in Hispanic/Latino Individuals of Diverse Genetic Ancestries. | Association of HSD17B13 and PNPLA3 With Liver Enzymes and Fibrosis in Hispanic/Latino Individuals of Diverse Genetic Ancestries.
Rutledge SM, Soper ER, Ma N, Pejaver V, Friedman SL, Branch AD, Kenny EE, Belbin GM, Abul-Husn NS. | 09/12/2023 |
| Structural basis of lipid-droplet localization of 17-beta-hydroxysteroid dehydrogenase 13. | Structural basis of lipid-droplet localization of 17-beta-hydroxysteroid dehydrogenase 13.
Liu S, Sommese RF, Nedoma NL, Stevens LM, Dutra JK, Zhang L, Edmonds DJ, Wang Y, Garnsey M, Clasquin MF., Free PMC Article | 09/1/2023 |
| The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma. | The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma.
Innes H, Morgan MY, Hampe J, Stickel F, Buch S. | 08/28/2023 |
| MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery. | MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery.
Kalinowski P, Smyk W, Nowosad M, Paluszkiewicz R, Michałowski Ł, Ziarkiewicz-Wróblewska B, Weber SN, Milkiewicz P, Lammert F, Zieniewicz K, Krawczyk M., Free PMC Article | 01/11/2023 |
| Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients. | Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients.
Gil-Gómez A, Rojas Á, García-Lozano MR, Muñoz-Hernández R, Gallego-Durán R, Maya-Miles D, Montero-Vallejo R, Gato S, Gallego J, Francés R, Soriano G, Ampuero J, Romero-Gómez M., Free PMC Article | 10/22/2022 |
| Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms. | Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.
Hudert CA, Adams LA, Alisi A, Anstee QM, Crudele A, Draijer LG, Furse S, Hengstler JG, Jenkins B, Karnebeek K, Kelly DA, Koot BG, Koulman A, Meierhofer D, Melton PE, Mori TA, Snowden SG, van Mourik I, Vreugdenhil A, Wiegand S, Mann JP, EU‐PNAFLD investigators., Free PMC Article | 07/30/2022 |
| HSD17B13 and other liver fat-modulating genes predict development of hepatocellular carcinoma among HCV-positive cirrhotics with and without viral clearance after DAA treatment. | HSD17B13 and other liver fat-modulating genes predict development of hepatocellular carcinoma among HCV-positive cirrhotics with and without viral clearance after DAA treatment.
Burlone ME, Bellan M, Barbaglia MN, Mocchetti G, Mallela VR, Minisini R, Rigamonti C, Pirisi M. | 04/2/2022 |
| The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD. | The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
Vilar-Gomez E, Pirola CJ, Sookoian S, Wilson LA, Liang T, Chalasani N., Free PMC Article | 02/5/2022 |
| Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis. | Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
Tang S, Zhang J, Mei TT, Zhang WY, Zheng SJ, Yu HB., Free PMC Article | 12/25/2021 |
| Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. | Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
Paternostro R, Staufer K, Traussnigg S, Stättermayer AF, Halilbasic E, Keritam O, Meyer EL, Stift J, Wrba F, Sipos B, Canbay A, Schlattjan M, Aigner E, Datz C, Stickel F, Schafmayer C, Hampe J, Buch S, Prager G, Munda P, Mandorfer M, Ferenci P, Trauner M., Free PMC Article | 10/23/2021 |
| Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort. | Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort.
Ting YW, Kong AS, Zain SM, Chan WK, Tan HL, Mohamed Z, Pung YF, Mohamed R., Free PMC Article | 09/25/2021 |
| Pediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant. | Pediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant.
Di Sessa A, Umano GR, Cirillo G, Passaro AP, Verde V, Cozzolino D, Guarino S, Marzuillo P, Miraglia Del Giudice E., Free PMC Article | 07/24/2021 |
| Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. | Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.
Scheiner B, Stättermayer AF, Schwabl P, Bucsics T, Paternostro R, Bauer D, Simbrunner B, Schmidt R, Marculescu R, Ferlitsch A, Peck-Radosavljevic M, Pinter M, Trauner M, Reiberger T, Ferenci P, Mandorfer M., Free PMC Article | 07/17/2021 |
| Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos. | Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos.
Kallwitz E, Tayo BO, Kuniholm MH, Daviglus M, Zeng D, Isasi CR, Cotler SJ. | 07/17/2021 |
| The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease. | The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
Sun DQ, Wang TY, Zheng KI, Zhang HY, Wang XD, Targher G, Byrne CD, Chen YP, Yuan WJ, Jin Y, Zheng MH. | 07/3/2021 |
| The rs72613567: TA Variant in the Hydroxysteroid 17-beta Dehydrogenase 13 Gene Reduces Liver Damage in Obese Children. | The rs72613567: TA Variant in the Hydroxysteroid 17-beta Dehydrogenase 13 Gene Reduces Liver Damage in Obese Children.
Di Sessa A, Umano GR, Cirillo G, Marzuillo P, Arienzo MR, Pedullà M, Miraglia Del Giudice E. | 06/26/2021 |
| HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis. | HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Wang P, Wu CX, Li Y, Shen N. | 05/22/2021 |
| Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. | Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers.
Stickel F, Lutz P, Buch S, Nischalke HD, Silva I, Rausch V, Fischer J, Weiss KH, Gotthardt D, Rosendahl J, Marot A, Elamly M, Krawczyk M, Casper M, Lammert F, Buckley TWM, McQuillin A, Spengler U, Eyer F, Vogel A, Marhenke S, von Felden J, Wege H, Sharma R, Atkinson S, Franke A, Nehring S, Moser V, Schafmayer C, Spahr L, Lackner C, Stauber RE, Canbay A, Link A, Valenti L, Grove JI, Aithal GP, Marquardt JU, Fateen W, Zopf S, Dufour JF, Trebicka J, Datz C, Deltenre P, Mueller S, Berg T, Hampe J, Morgan MY. | 05/8/2021 |
| Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. | Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.
Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. | 05/1/2021 |
| Genetic Susceptibility to Chronic Liver Disease in Individuals from Pakistan. | Genetic Susceptibility to Chronic Liver Disease in Individuals from Pakistan.
Raja AM, Ciociola E, Ahmad IN, Dar FS, Naqvi SMS, Moaeen-Ud-Din M, Kaukab Raja G, Romeo S, Mancina RM., Free PMC Article | 02/27/2021 |
| A common loss-of-function variant in HSD17B13 (rs72613567:TA) was recently found to protect from chronic liver disease. Whether the variant confers protection from specific risk factors for liver disease is unclear. We tested the association of rs72613567 with plasma levels of alanine transaminase (ALT) and clinical liver disease and mortality in 111,612 individuals from the Danish general population | High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
Gellert-Kristensen H, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. | 07/18/2020 |
| rs72613567 loss of function variant is protective of hepatocellular carcinoma development in patients with alcoholic liver disease | A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.
Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, Imbeaud S, Bayard Q, Gustot T, Deviere J, Bioulac-Sage P, Calderaro J, Ganne-Carrié N, Laurent A, Blanc JF, Guyot E, Sutton A, Ziol M, Zucman-Rossi J, Nault JC. | 06/27/2020 |
| lipid droplet-associated retinol dehydrogenase with a role in nonalcoholic fatty liver disease | 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
Ma Y, Belyaeva OV, Brown PM, Fujita K, Valles K, Karki S, de Boer YS, Koh C, Chen Y, Du X, Handelman SK, Chen V, Speliotes EK, Nestlerode C, Thomas E, Kleiner DE, Zmuda JM, Sanyal AJ, (for the Nonalcoholic Steatohepatitis Clinical Research Network), Kedishvili NY, Liang TJ, Rotman Y., Free PMC Article | 05/30/2020 |
| the rs72613567 A-INS allele reduces the risk of NASH and progressive liver damage | Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease.
Pirola CJ, Garaycoechea M, Flichman D, Arrese M, San Martino J, Gazzi C, Castaño GO, Sookoian S., Free PMC Article | 02/15/2020 |